Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report

J. Prosvicova, S. Lukesova, J. Kopecky, J. Grim, Z. Papik, R. Kolarova, B. Navratilova, P. Dubreuil, J. Agopian, C. Mansfield, A. Moussy, O. Hermine

. 2015 ; 159 (4) : 695-697. [pub] 20151127

Jazyk angličtina Země Česko

Typ dokumentu kazuistiky, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17004314

BACKGROUND: Malignant melanoma in the gastrointestinal tract may be primary or metastatic. Mucosal melanoma is a quite rare and aggressive disease, growing hidden and diagnosed with a certain delay which makes treatment difficult. CASE REPORT: The authors present the first patient with c-kit exon 11 mutated primary esophageal melanoma treated with oral tyrosine kinase inhibitor masitinib. A 55-year-old-man presented with esophageal melanoma metastising into visceral organs and to the brain. The patient showed objective and clinical significant therapeutic response to masitinib. After initiation of masitinib, dysphagia and odynophagia disappeared within 1 week. Following 1 month of treatment, computed tomography showed a regression in the number and size of brain metastatic lesions and regression in visceral lesions. This therapeutic response, despite the aggressive disease on treatment initiation, effectively enabled the patient to have 6 months of quality life. CONCLUSION: This report corroborates the plausibility of treating advanced melanoma carrying a mutation of KIT with masitinib. It also raises the question of masitinib treatment beyond progression. Additionally, the observed masitinib treatment effect on the brain suggests accumulation of therapeutically relevant concentration of masitinib in the central nervous system. This observation has possible ramifications for treatment of intracranial neoplasms.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17004314
003      
CZ-PrNML
005      
20170308085106.0
007      
ta
008      
170127s2015 xr a f 000 0|eng||
009      
AR
024    7_
$a 10.5507/bp.2015.061 $2 doi
024    7_
$a 10.5507/bp.2015.061 $2 doi
035    __
$a (PubMed)26725706
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Prošvicová, Jarmila $u Department of Clinical Oncology, County Hospital, Nachod, Czech Republic $7 xx0228344
245    10
$a Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report / $c J. Prosvicova, S. Lukesova, J. Kopecky, J. Grim, Z. Papik, R. Kolarova, B. Navratilova, P. Dubreuil, J. Agopian, C. Mansfield, A. Moussy, O. Hermine
520    9_
$a BACKGROUND: Malignant melanoma in the gastrointestinal tract may be primary or metastatic. Mucosal melanoma is a quite rare and aggressive disease, growing hidden and diagnosed with a certain delay which makes treatment difficult. CASE REPORT: The authors present the first patient with c-kit exon 11 mutated primary esophageal melanoma treated with oral tyrosine kinase inhibitor masitinib. A 55-year-old-man presented with esophageal melanoma metastising into visceral organs and to the brain. The patient showed objective and clinical significant therapeutic response to masitinib. After initiation of masitinib, dysphagia and odynophagia disappeared within 1 week. Following 1 month of treatment, computed tomography showed a regression in the number and size of brain metastatic lesions and regression in visceral lesions. This therapeutic response, despite the aggressive disease on treatment initiation, effectively enabled the patient to have 6 months of quality life. CONCLUSION: This report corroborates the plausibility of treating advanced melanoma carrying a mutation of KIT with masitinib. It also raises the question of masitinib treatment beyond progression. Additionally, the observed masitinib treatment effect on the brain suggests accumulation of therapeutically relevant concentration of masitinib in the central nervous system. This observation has possible ramifications for treatment of intracranial neoplasms.
650    _2
$a nádory mozku $x farmakoterapie $x sekundární $7 D001932
650    _2
$a nádory jícnu $x farmakoterapie $7 D004938
650    _2
$a exony $7 D005091
650    _2
$a fatální výsledek $7 D017809
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melanom $x farmakoterapie $x sekundární $7 D008545
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $x genetika $7 D009154
650    _2
$a inhibitory proteinkinas $x terapeutické užití $7 D047428
650    _2
$a protoonkogenní proteiny c-kit $x genetika $7 D019009
650    _2
$a thiazoly $x terapeutické užití $7 D013844
655    _2
$a kazuistiky $7 D002363
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lukesova, Sarka $u Department of Clinical Oncology, County Hospital, Nachod, Czech Republic; Department of Clinical Microbiology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Hradec Kralove
700    1_
$a Kopecký, Jindřich, $u Department of Clinical Oncology and Radiotherapy, University Hospital in Hradec Kralove $d 1982- $7 xx0129613
700    1_
$a Grim, Jiří $u Department of Clinical Oncology and Radiotherapy, University Hospital in Hradec Kralove. $7 xx0143078
700    1_
$a Papík, Zdeněk $u Endoscopic Centre, County Hospital, Nachod $7 _AN064039
700    1_
$a Kolářová, Renata, $u Endoscopic Centre, County Hospital, Nachod $d 1973- $7 mzk2005269826
700    1_
$a Navratilova, Blanka $u Department of Histopathology, County Hospital Nachod
700    1_
$a Dubreuil, Patrice $u Inserm, U1068, CRCM (Signaling, Hematopoiesis and Mechanism of Oncogenesis); Institut Paoli-Calmettes, Aix-Marseille Univ, F-13284; CNRS, UMR7258, Marseille, F-13009, France. AB Science, Paris, France
700    1_
$a Agopian, Julie $u AB Science, Paris, France $7 gn_A_00002223
700    1_
$a Mansfield, Colin $u AB Science, Paris, France
700    1_
$a Moussy, Alan $u AB Science, Paris, France
700    1_
$a Hermine, Olivier $u AB Science, Paris, France. Hospital Necker, Paris; CNRS UMR 8147, Department of Hematology, Universite Paris V Rene Descartes, Paris; Institut Imagine, Universite Sorbonne Paris cite, Paris, France
773    0_
$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic $x 1213-8118 $g Roč. 159, č. 4 (2015), s. 695-697
856    41
$u http://biomed.papers.upol.cz/ $y domovská stránka časopisu
910    __
$a ABA008 $b A 1502 $c 958 $y 4 $z 0
990    __
$a 20170127 $b ABA008
991    __
$a 20170307140906 $b ABA008
999    __
$a ok $b bmc $g 1192529 $s 964930
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 159 $c 4 $d 695-697 $e 20151127 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
LZP    __
$b NLK118 $a Pubmed-20170127

Najít záznam

Citační ukazatele

Možnosti archivace